RECIST criteria: our experience in daily practice
نویسندگان
چکیده
Content organisation Our cases will be presented in a pictorial essay mode. Key differential diagnostic points will be highlighted in the discussion of each case. It is important to consider: Complete knowledge of clinical-oncologic status and treatments time points. Recognition of smallest measured value (NADIR) between time points for adequate selection of comparative review. Sum of target lesions (baseline and current time points) including percentage of change. Select no more than two target lesions by sector. Complete knowledge of actinic extension field which often could present different behavior than other lesional sites. Local tumour growth over vital organs regardless strict RECIST criteria in exceptional cases. Further criteria utilization in line with oncological disease being studied (mRECIST criteria for hepatocellular carcinoma or CHOI criteria for GIST). Use of SUL on baseline PET CT studies with greater accuracy in assessing response on further evaluations (PERCIST criteria).
منابع مشابه
Response assessment in daily practice: RECIST and its modifications
Response Evaluation Criteria for Solid Tumours (RECIST) were introduced in 2000 to provide a standardized method for assessing response to treatments in the clinical trial setting [1]. The RECIST Working Group has updated RECIST to version 1.1 [2]. The revised version has maintained assessment of tumour burden using sum of the diameters and continues to use uni-dimensional measurements. The res...
متن کاملThe Assessment of Tumor Response by Measuring the Single Largest Lesion per Organ in Metastatic Tumors: A Pooled Analysis of Previously Reported Data
BACKGROUND The RECIST 1.1 adopted a total of five target lesions to be measured, with a maximum of two lesions per organ. To the best of our knowledge, the criterion of two target lesions per organ in the RECIST 1.1 is arbitrary and has not been supported by any objective evidence. Recently, we reported that the modified RECIST 1.1 (measuring the single largest lesion in each organ) showed a hi...
متن کاملIdeal number of target lesions per organ to measure in metastatic colorectal cancer
The Response Evaluation Criteria in Solid Tumors (RECIST 1.1) guideline states that the two largest lesions per organ should be measured as target lesions for assessment of the tumor response. This criterion is considered to be arbitrary and, to the best of our knowledge, has not been supported by any objective evidence. The present study hypothesized that measuring the single largest lesion in...
متن کامل'Please, desist RECIST criteria in GIST, at least in me'.
for 2 months. A control CT showed central necrosis of the lesions which were essentially unchanged. However, the patient reported that the symptom of abdominal pain did no longer exist. The patient was advised to take imatinib mesylate for 2 more months. A subsequent CT scan again showed no change in the diameter of the mass, so the RECIST criteria again failed to meet our expectations. As a co...
متن کاملTool Support to Enable Evaluation of the Clinical Response to Treatment
Objective criteria for measuring response to cancer treatment are critical to clinical research and practice. The National Cancer Institute has developed the Response Evaluation Criteria in Solid Tumors (RECIST) method to quantify treatment response. RECIST evaluates response by assessing a set of measurable target lesions in baseline and follow-up radiographic studies. However, applying RECIST...
متن کامل